SYRE vs ARRY vs PRTA vs TRMB vs PTGX

For growth investors, Array Technologies, Inc.

(ARRY) is the stronger pick with 40. 2% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Trimble Inc. (TRMB) offers the better valuation at 35. 3x trailing P/E (20. 0x forward), making it the more compelling value choice. Analysts rate Spyre Therapeutics, Inc. (SYRE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Array Technologies, Inc.

is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +238. 8%, compared to -67. 7% for Array Technologies, Inc. (ARRY). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus ARRY's -77. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 25β versus Array Technologies, Inc. 's 2. 32β — meaning ARRY is approximately 824% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 3% for Array Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Array Technologies, Inc.

(ARRY) is pulling ahead at 40. 2% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Array Technologies, Inc. grew EPS 62. 6% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Trimble Inc.

(TRMB) is the more profitable company, earning 11. 8% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TRMB leads at 16. 9% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Array Technologies, Inc.

(ARRY) trades at 11. 7x forward P/E versus 42. 7x for Prothena Corporation plc — 30. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 80. 4% to $19. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +744. 9% 10Y return). Array Technologies, Inc. (ARRY) carries a higher beta of 2. 32 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTGX: +744. 9%, ARRY: -77. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SYRE (Healthcare) and ARRY (Energy) and PRTA (Healthcare) and TRMB (Technology) and PTGX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SYRE is a mid-cap quality compounder stock; ARRY is a small-cap high-growth stock; PRTA is a small-cap quality compounder stock; TRMB is a mid-cap quality compounder stock; PTGX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.